Drug Profile


Alternative Names: Jinarc; OPC 61815 injection; OPC-156; OPC-41061; Samsca; Samsca granules 1%

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Otsuka America Pharmaceutical; Otsuka Pharmaceutical
  • Class Antihypertensives; Benzazepines; Heart failure therapies
  • Mechanism of Action Diuretics; Vasopressin V2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autosomal dominant polycystic kidney disease; Polycystic kidney disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Autosomal dominant polycystic kidney disease; Cardiac oedema; Hyponatraemia; Oedema
  • Registered Ascites; Heart failure; Renal failure
  • Phase II Benign prostatic hyperplasia
  • Phase I Unspecified

Most Recent Events

  • 20 Aug 2017 Phase-II clinical trials in Heart failure (In adults, In the elderly) in Japan (IV) (NCT03254108) (JapicCTI-173676)
  • 18 Aug 2017 Phase-III clinical trials in Heart failure (In infants, In children, In adolescents) in Japan (PO; Granules and Tablets) (JapicCTI-173674)
  • 22 May 2017 Otsuka pharmaceuticals completes the phase III trial for Autosomal-dominant polycystic kidney disease in USA, Argentina, Canada, Czech Republic, Denmark, Germany, Hungary, Australia, France, Romania, Russia, Israel, Italy, Netherlands, Norway, Poland, Puerto Rico, South Africa, Spain, Sweden, Belgium and United Kingdom (PO) (NCT02160145)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top